Understanding how a specific gene affects blood cell development after cancer treatment
The role of SRCAP in therapy related clonal hematopoiesis
This study is looking at how changes in a specific gene called SRCAP might affect people who develop blood cancers after chemotherapy or radiation, with the goal of helping doctors better understand and prevent these serious conditions in cancer patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11024083 on NIH RePORTER |
What this research studies
This research investigates the role of the SRCAP gene in the development of therapy-related myeloid neoplasms (t-MN), which can occur after chemotherapy or radiation. The study aims to identify how mutations in SRCAP contribute to the expansion of blood cell progenitors and the risk of developing these serious conditions. By examining the genetic and epigenetic changes that occur in patients exposed to cytotoxic therapies, the research seeks to improve our understanding of clonal hematopoiesis and its progression to malignancy. This could lead to better risk assessment and preventive strategies for patients undergoing cancer treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults who have undergone chemotherapy or radiation therapy and may be at risk for developing therapy-related blood cancers.
Not a fit: Patients who have not received cytotoxic therapies or those with pre-existing blood disorders may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could help identify patients at high risk for developing serious blood cancers after cancer treatment, allowing for earlier interventions.
How similar studies have performed: Previous research has shown that understanding genetic mutations in hematopoietic cells can lead to significant advancements in predicting and preventing blood cancers, suggesting this approach has potential for success.
Where this research is happening
Boston, United States
- Brigham and Women's Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Sperling, Adam — Brigham and Women's Hospital
- Study coordinator: Sperling, Adam
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.